Publications by authors named "Olusola Sogbein"

Article Synopsis
  • * Bortezomib is a notable proteasome inhibitor approved for multiple myeloma that targets the 26S proteasome, affecting various cancer-related pathways to inhibit tumor growth.
  • * Despite its effectiveness, Bortezomib has side effects like peripheral neuropathy and kidney issues, prompting the need for further research into its mechanisms and exploring new proteasome inhibitors for cancer treatment.
View Article and Find Full Text PDF

Membranous lupus nephritis associated with anti-GBM antibodies is a rare entity, particularly in lupus nephritis patients who are serologically negative for ANA and anti-dsDNA with normal complement levels. We present an unusual case of a patient initially diagnosed with anti-GBM disease whose repeat biopsy demonstrated combined focal proliferative and membranous lupus nephritis (III + V). The first biopsy showed a granular linear pattern, and the second biopsy had multiple electron dense deposits in the subendothelial, epithelial, and mesangial regions along with podocyte effacement.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Olusola Sogbein"

  • - Olusola Sogbein's recent research focuses on the therapeutic mechanisms and effects of proteasome inhibitors in cancer treatment, particularly highlighting Bortezomib's role in managing various malignancies such as multiple myeloma and mantle cell lymphoma.
  • - The author investigates complex immunological conditions, specifically the merging of membranous lupus nephritis and anti-GBM disease, showcasing an unusual case that highlights the diagnostic challenges and mechanisms involved in these diseases.
  • - Sogbein's work underscores the intricate relationship between aberrant proteasome activity and cancer pathology while also exploring the rarity and specificity of autoimmune responses in nephrological conditions, bridging both oncology and nephrology disciplines.